U.S. Patent Disclosures
Lpath Inc., of San Diego, received U.S. Patent Nos. 8,025,877, and 8,026,342, which claim methods and composition of matter for its anti-sphingosine-1-phosphate antibody, sonepcizumab, the active component in the firm's lead compounds iSONEP and ASONEP.
